C07K 2317/50
Characterized by immunoglobulin fragments
Official title: characterized by immunoglobulin fragments
C07K2317/50 (Characterized by immunoglobulin fragments) appears on 16,011 US grants and 30,827 published applications in this corpus.
Search patents in C07K- Granted patents
- 16,011
- Published applications
- 30,827
- Assignees
- 5,503
- Inventors
- 36,049
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 3 | 0 |
| 1995 | 2 | 0 |
| 1996 | 15 | 0 |
| 1997 | 30 | 0 |
| 1998 | 55 | 0 |
| 1999 | 74 | 0 |
| 2000 | 64 | 0 |
| 2001 | 68 | 24 |
| 2002 | 59 | 118 |
| 2003 | 55 | 273 |
| 2004 | 61 | 286 |
| 2005 | 69 | 376 |
| 2006 | 112 | 422 |
| 2007 | 118 | 412 |
| 2008 | 182 | 457 |
| 2009 | 233 | 718 |
| 2010 | 352 | 770 |
| 2011 | 403 | 882 |
| 2012 | 505 | 863 |
| 2013 | 570 | 967 |
| 2014 | 606 | 1130 |
| 2015 | 731 | 1280 |
| 2016 | 843 | 1543 |
| 2017 | 925 | 1642 |
| 2018 | 965 | 1616 |
| 2019 | 1045 | 1718 |
| 2020 | 1142 | 1986 |
| 2021 | 1147 | 2208 |
| 2022 | 1096 | 2207 |
| 2023 | 1017 | 2312 |
| 2024 | 1237 | 2559 |
| 2025 | 1306 | 2275 |
| 2026 | 912 | 1783 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C07K 2317/56Variable region, i.e. vh and/or vlIndexing code12,087
- C07K 2317/52Constant or fc regionIndexing code4,722
- C07K 2317/55Fab or fab'Indexing code4,445
- C07K 2317/515Complete light chain, i.e. vl + clIndexing code1,285
- C07K 2317/51Complete heavy chain or fd fragment, i.e. vh + ch1Indexing code1,253
- C07K 2317/54F2Indexing code1,185
Recent patents
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- Enhancement of immune response with oral immunoglobulin polypeptides6 Oct 2026US 12,752,004 B2Iogenetics, LLC
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Inducible chimeric antigen receptor and application thereof6 Oct 2026US 12,752,007 B2Beijing Tiantan Hospital, Capital Medical University
- Anti-galectin 3 antibodies and their use in epilepsy and related diseases6 Oct 2026US 12,752,015 B2Sunmed Therapeutic Limited
- Methods for treatment using anti-alpha4beta7 antibody8 Oct 2026US 2026/0306636 A1Takeda Pharmaceutical Company Limited
- Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof8 Oct 2026US 2026/0306651 A1MediLink Therapeutics (Suzhou) Co., Ltd.
- Lipid nanoparticles and methods of manufacture and use thereof8 Oct 2026US 2026/0306659 A1Ablynx N. V.
- Radiolabeled met binding proteins for immuno-pet imaging8 Oct 2026US 2026/0306682 A1Regeneron Pharmaceuticals, Inc.
- Targeted engineered interferon and uses thereof8 Oct 2026US 2026/0308221 A1Orionis Biosciences BV
Most cited
By later US patents
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996